BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · IEX Real-Time Price · USD
0.352
+0.010 (3.05%)
Jul 2, 2024, 3:58 PM EDT - Market closed
Company Description
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease.
It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.
BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
BiomX Inc.
| Country | Israel |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Jonathan Eitan Solomon MBA |
Contact Details
Address: 22 Einstein St., 4th Floor Ness Ziona, L3 7414003 Israel | |
| Phone | (972) 72 394 2377 |
| Website | biomx.com |
Stock Details
| Ticker Symbol | PHGE |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739174 |
| CUSIP Number | 09090D103 |
| ISIN Number | US09090D1037 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan Eitan Solomon MBA | Chief Executive Officer and Director |
| Dr. Merav Bassan Ph.D. | Chief Development Officer |
| Marina Wolfson CPA | Chief Financial Officer and Secretary (Leave of Absence) |
| Prof. Rotem Sorek Ph.D. | Scientific Founder |
| Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
| Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
| Avraham Gabay | Interim Chief Financial Officer |
| Inbal Benjamini-Elran | C.H.R.O |
| Assaf Oron | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | ARS | Filing |
| Jun 17, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 13, 2024 | PRER14A | Filing |
| May 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 30, 2024 | 8-K/A | [Amend] Current report |
| May 30, 2024 | 8-K | Current Report |
| May 28, 2024 | PRE 14A | Other preliminary proxy statements |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Apr 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |